Silexion Therapeutics Corp ( NASDAQ:SLXN – Free Report ) – Analysts at Litchfield Hills Research issued their FY2027 EPS estimates for shares of Silexion Therapeutics in a report issued on Monday, September 21st. Litchfield Hills Research analyst T. O’neill anticipates that the company will post earnings of ($1.84) per share for the year. The consensus estimate for Silexion Therapeutics’ current full-year earnings is ($4.70) per share.
Get Silexion Therapeutics alerts: Silexion Therapeutics ( NASDAQ:SLXN – Get Free Report ) last issued its quarterly earnings results on Saturday, August 15th. The company reported ($5.17) EPS for the quarter, topping the consensus estimate of ($21.20) by $16.03.
Several other research analysts have also recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Friday, September 11th. Maxim Group cut Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Silexio...